AbbVie Inc. (NYSE:ABBV) Shares Bought by B & T Capital Management DBA Alpha Capital Management

B & T Capital Management DBA Alpha Capital Management grew its stake in AbbVie Inc. (NYSE:ABBV) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,641 shares of the company’s stock after purchasing an additional 419 shares during the period. B & T Capital Management DBA Alpha Capital Management’s holdings in AbbVie were worth $4,912,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Retirement Wealth Solutions LLC acquired a new position in shares of AbbVie during the fourth quarter worth about $35,000. Brooklyn Investment Group increased its position in AbbVie by 29.6% during the 4th quarter. Brooklyn Investment Group now owns 15,338 shares of the company’s stock worth $2,725,000 after purchasing an additional 3,502 shares during the period. Whitener Capital Management Inc. increased its position in AbbVie by 0.8% during the 4th quarter. Whitener Capital Management Inc. now owns 38,266 shares of the company’s stock worth $6,800,000 after purchasing an additional 309 shares during the period. Helen Stephens Group LLC lifted its holdings in shares of AbbVie by 4.7% in the 4th quarter. Helen Stephens Group LLC now owns 1,369 shares of the company’s stock valued at $243,000 after buying an additional 61 shares during the period. Finally, Sax Wealth Advisors LLC boosted its stake in shares of AbbVie by 14.0% in the fourth quarter. Sax Wealth Advisors LLC now owns 6,594 shares of the company’s stock valued at $1,172,000 after buying an additional 810 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

ABBV stock opened at $171.49 on Friday. The stock has a 50-day simple moving average of $175.78 and a 200-day simple moving average of $184.47. The firm has a market cap of $303.05 billion, a P/E ratio of 59.55, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.92 by $0.08. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.95 earnings per share. On average, equities analysts predict that AbbVie Inc. will post 10.06 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a dividend of $1.64 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, January 15th. AbbVie’s dividend payout ratio (DPR) is currently 215.28%.

Insider Transactions at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.25% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wolfe Research began coverage on AbbVie in a research report on Friday, November 15th. They issued an “outperform” rating and a $205.00 price objective for the company. Truist Financial cut their price target on shares of AbbVie from $215.00 to $211.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. BMO Capital Markets lowered their target price on shares of AbbVie from $228.00 to $208.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 12th. Daiwa Capital Markets lowered AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price target on the stock. in a research note on Thursday, December 5th. Finally, Leerink Partners upgraded AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price target on the stock in a report on Friday, November 22nd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $205.50.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.